Permixon, 160 mg capsules 30 pcs

Permixon has a complex effect on the pathogenesis and symptoms of benign prostatic hyperplasia due to the complementary effects of the constituent ingredients of this herbal extract.

Permixon has anti-androgenic, anti-inflammatory, anti-inflammatory and anti-proliferative effects, which are selectively expressed at the level of the prostate gland. At the same time the preparation does not influence the level of sex hormones in blood, does not cause deterioration of sexual functions, libido and potency and does not change the level of serum PSA (prostate-specific antigen).

The local anti-androgenic effect of Permixon is associated with the inhibition of 5-alpha-reductase enzyme of types I and II, responsible for the conversion of testosterone in the prostate into its active form – dihydrotestosterone, and reduction of its binding to specific receptors. Reducing the formation of dihydrotestosterone leads to a decrease in further growth of the prostate.

Local anti-inflammatory effect is due to the impact of lipidosterol extract serenoa creeping on the main mediators of cellular inflammation – inhibits the activity of phospholipase A2, cyclooxygenase and lipooxygenase.

Permixon during the first weeks of treatment reduces capillary permeability and vascular stasis, relieves edema and inflammation of the prostate, eliminates compression of the bladder neck and urinary tract and, like alpha-blockers, improves urodynamic indices.

Local antiproliferative action of the preparation is manifested by decrease of activity of growth factors (first of all epidermal and fibroblastic) and acceleration of apoptosis processes of prostate cells which is reflected in inhibition of growth and subsequent decrease of prostate gland volume.

These properties of the preparation help to reduce pathological symptoms of benign prostatic hyperplasia (dysuria, pollakiuria, nycturia, painful sensations and tension while urination, incomplete emptying of the bladder) and increase the volume and force of urination.

On the other hand, Permixon promotes inhibition of further growth and volume of the prostate gland.

Indications

Benign hyperplasia (adenoma) of the prostate gland stages I and II.

Pharmacological effect

Permixon has a complex effect on the pathogenesis and symptoms of benign prostatic hyperplasia, which is due to the complementary effects of the constituent ingredients of this plant extract.

Permixon has antiandrogenic, anti-inflammatory, decongestant and antiproliferative effects, selectively manifested at the level of the prostate gland. At the same time, the drug does not affect the level of sex hormones in the blood, does not cause deterioration in sexual functions, libido, potency and does not change the level of serum PSA (prostate-specific antigen).

The local antiandrogenic effect of Permixon is associated with inhibition of the enzyme 5-alpha reductase types I and II, which is responsible for the conversion of testosterone in the prostate gland into its active form – dihydrotestosterone, and a decrease in the binding of the latter to specific receptors. A decrease in the formation of dihydrotestosterone entails a decrease in further growth of prostate volume.

The local anti-inflammatory effect is due to the influence of the lipidosterol extract of saw palmetto on the main mediators of cellular inflammation – it inhibits the activity of phospholipase A2, cyclooxygenase and lipoxygenase.

During the first weeks of treatment, Permixon reduces capillary permeability and vascular stasis, relieves swelling and inflammation of the prostate, eliminates compression of the bladder neck and urinary canal, and, like alpha blockers, improves urodynamics.

The local antiproliferative effect of the drug is manifested by a decrease in the activity of growth factors (primarily epidermal and fibroblastic) and acceleration of the processes of apoptosis of prostate cells, which is reflected in inhibition of growth and subsequent decrease in the volume of the prostate gland.

These properties of the drug contribute, on the one hand, to a reduction in the pathological symptoms of benign prostatic hyperplasia (dysuria, pollakiuria, nocturia, pain and a feeling of tension when urinating, incomplete emptying of the bladder), and an increase in the volume and force of urination.

On the other hand, Permixon helps inhibit further growth and volume of the prostate gland.

Active ingredient

Creeping palm fruit extract

Composition

1 capsule contains:
Active substance:
Saw palmetto fruit extract lipidosterol – Serenoa repens – (LSESR) – 160 mg.
Excipients:
macrogoal 10000
Capsule (base and cap) No. 1 consists of:
titanium dioxide,
indigo carmine,
iron oxide yellow,
gelatin.

Contraindications

Hypersensitivity to the components of the drug.

Side Effects

In some cases, nausea, heartburn, and gastralgia may occur, which usually disappear when taking the drug with food. In rare cases, allergic reactions.

Interaction

Compatible with drugs most often used in the treatment of obstructive and inflammatory diseases of the prostate gland (antibiotics, uroantiseptics, anti-inflammatory drugs).

Storage conditions

At a temperature not exceeding 25 °C.

Shelf life

3 years

Manufacturer

Pierre Fabre Medicine Production, France